Table 2. Summary of results from the second phase of EQA.
| Sample | Correct results | Kit | CT (Mean±SD) | N of participants* | |
|---|---|---|---|---|---|
| upE | ORF1a | ||||
| A | 100% | AccuPower | 28.1 ± 0.6 | 29.8 ± 0.2 | 4 |
| PowerChek | 25.8 ± 0.9 | 26.5 ± 0.7 | 31 | ||
| DiaPlexQ | 28.0 ± 1.9 | 26.8 ± 2.2 | 9 | ||
| Others* | 26.5 ± 1.3 | 27.1 ± 1.4 | 3 | ||
| Total | 26.6 ± 1.6 | 27.0 ± 1.6 | 47 | ||
| B | 100% | AccuPower | 31.6 ± 0.7 | 33.3 ± 0.2 | 4 |
| PowerChek | 29.5 ± 1.0 | 30.2 ± 0.9 | 31 | ||
| DiaPlexQ | 30.5 ± 1.8 | 30.6 ± 2.4 | 9 | ||
| Others* | 30.1 ± 1.3 | 30.7 ± 1.4 | 3 | ||
| Total | 30.2 ± 1.5 | 30.7 ± 1.6 | 47 | ||
| C | 100% | AccuPower | Negative | Negative | 4 |
| PowerChek | Negative | Negative | 31 | ||
| DiaPlexQ | Negative | Negative | 9 | ||
| Others* | Negative | Negative | 3 | ||
| Total | Negative | Negative | 47 | ||
*This includes laboratory-developed test, MERS-CoV Detection kit (Nanobiosys, Seoul, Korea) and ModularDx kit MERS-CoV (TIB MOLBIOL, Berlin, Germany).
Abbreviations: EQA, external quality assessment; CT, threshold cycle.